Rx Stock Declines Leave Novartis, P&G With More Options
Executive Summary
Novartis is riding high expectations for the COX-2 inhibitor Prexige to a new level of prestige on Wall Street
You may also be interested in...
Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks
As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry
Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks
As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry
Forest Excels: Celexa, Lexapro Help Company In Down Quarter On Wall Street
Forest Labs is off to a fast start in fourth quarter trading, as the company has found a winning formula during a prolonged down market for brand name pharmaceutical stocks